Lithium normalizes ASD-related neuronal, synaptic, and behavioral phenotypes in DYRK1A-knockin mice.

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Dyrk1A deficiency is associated with neurodevelopmental disorders like intellectual disability (ID) and autism spectrum disorders (ASD).
• Previous studies in mice showed Dyrk1a haploinsufficiency leads to ASD-related phenotypes, but underlying mechanisms and human mutations' effects were unclear.

Purpose of the Study:

• To investigate the pathological mechanisms of a human DYRK1A mutation linked to ASD using a mouse model.
• To evaluate the therapeutic potential of early lithium treatment on Dyrk1A mutation-induced phenotypes.

Main Methods:

• Generated Dyrk1a-knockin mice (Dyrk1a-I48K) with a specific human ASD patient mutation.
• Phenotypic analysis included brain volume, behavior, dendritic morphology, and synaptic function.
• Phospho-proteomic analysis identified altered signaling pathways and synaptic proteins.
• Assessed the effects of early chronic lithium treatment on mutant mice.

Main Results:

• Dyrk1a-I48K mice exhibited microcephaly, social and cognitive deficits, dendritic shrinkage, and excitatory synaptic dysfunction.
• Altered phospho-proteomic patterns revealed dysregulation in key signaling and synaptic pathways.
• Early lithium treatment significantly rescued brain volume, behavioral deficits, dendritic structure, synaptic function, and proteomic alterations.

Conclusions:

• Signaling and synaptic alterations are key contributors to Dyrk1A mutation-associated neurodevelopmental phenotypes.
• Early intervention with lithium demonstrates long-lasting therapeutic effects, preventing severe outcomes in juvenile and adult stages.